Brendan P. Eckelman
Equibles does not estimate personal net worth.
About Brendan P. Eckelman
Inhibrx Biosciences, Inc. reported in an 8-K filed April 1, 2025 that Brendan P. Eckelman resigned as EVP, Chief Scientific Officer, effective March 31, 2025. The proxy statement of Inhibrx Biosciences, Inc. reports total compensation of $2,627,592 for Brendan P. Eckelman in fiscal 2024, including a base salary of $535,600. Disclosed compensation is on record for 2 fiscal years.
“On March 31, 2025, Brendan P. Eckelman, Ph.D. informed the Company of his intention to resign as EVP, Chief Scientific Officer of the Company, effective immediately, to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer.”
Affiliation history
-
Inhibrx Biosciences, Inc. (INBX)
Proxy statement
Start not stated–2025-03-31
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Inhibrx Biosciences, Inc. (INBX) | Former Chief Scientific Officer | $535,600 | $2,627,592 |
| 2023 | Inhibrx Biosciences, Inc. (INBX) | Former Chief Scientific Officer | $520,000 | $1,451,958 |